Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanChol Safety and Immunogenicity in Healthy Volunteers
NCT05657782Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PanChol in cholera (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Incidence of solicited and unsolicited adverse events at 180 days and Seroconversion of vibriocidal titers at 180 days. Started Dec 2022; status: recruiting.
02
Drugs
PanChol
03
Conditions
cholera
Beyond the preview
Go deeper on NCT05657782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657782.